Internship

Intern – Environmental Health & Safety

Ehs

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Paid internship at South San Francisco headquarters.

Category
Lab & Research
Environmental Sciences
Requirements
  • Currently enrolled in university, pursuing a Bachelor’s or Master’s Degree in Occupational Health & Safety, Public Heath, Industrial Safety, Industrial Hygiene, Environmental Engineering, Environmental Sciences, Chemical Engineering, Biological Sciences, or a related field
  • Strong analytical, quantitative, and problem-solving skills
  • Excellent communication and interpersonal skills
  • Ability to work independently and as part of a team
  • Basic knowledge of EHS regulations and standards is a plus
  • Proficiency in Microsoft Office Suite (Word, Excel, PowerPoint), Smart Sheet
Responsibilities
  • Support EHS Program Implementation by assisting with the development and implementation of EHS policies and procedures
  • Help ensure compliance with OSHA, EPA, and other relevant regulations by maintaining records and assisting in audits and inspections
  • Assist with the documentation and reporting of workplace incidents, near misses, and corrective actions
  • Support with updating EHS training content and employee training profiles
  • Help track and analyze EHS metrics, including incidents, safety observations, and waste management, and assist with preparing reports
  • Assist in performing risk assessments to identify potential hazards and implement measures to mitigate them
  • Assist in the development of EHS communications
  • Support ergonomic workspace evaluations
  • Assist with sustainability projects and initiatives

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?